Risk for ALCL appears very low among women with breast implants, but still greater than that of women who do not have implants. This cancer can be identified through symptoms such as pain, lumps, swelling or breasts asymmetry. Of the 231 medical device reports that included information on the implant surface, 203 were reported to be textured implants and 28 were smooth implants. In 2016, there were several advances in the description of the disease and treatment recommendations. Several recent journal articles explore the risk factors for BIA-ALCL, including the methods used to create surface texture of the implant and the role of biofilm in causing disease, among others. Most cases of breast implant-associated ALCL are treated by removal of the implant and the capsule surrounding the implant and some cases have been treated by chemotherapy and radiation. Prophylactic breast implant removal in patients without symptoms or other abnormality is not recommended. FDA recommends to acquire good information about breast implants before agreeing to surgery.